The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000545369
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
16/04/2026
Date registered
Help: Date registered
30/04/2026
Date last updated
Help: Date last updated
30/04/2026
Date data sharing statement initially provided
Help: Data sharing statement date
30/04/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Quadriceps versus Hamstrings Tendon Graft for Medial Patellofemoral Ligament (MPFL) Reconstruction in Paediatric Patients
Scientific title
Effect of Quadriceps versus Hamstrings Tendon Graft for Medial Patellofemoral Ligament (MPFL) Reconstruction on Knee Pain, Symptoms and Stability in Paediatric Patients: A Randomised Controlled Trial
Additional trial identifiers [1] 316735 0
Nil
Universal Trial Number (UTN)
U1111-1336-9964
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
Patellofemoral Instability 341013 0
Medial Patellofemoral Ligament Reconstruction 341636 0
Condition category
Condition code
Musculoskeletal 337161 337161 0 0
Other muscular and skeletal disorders
Surgery 337162 337162 0 0
Surgical techniques
Injuries and Accidents 337163 337163 0 0
Other injuries and accidents

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This is a prospective randomized controlled trial (RCT) comparing outcomes in paediatric patients undergoing medial patellofemoral ligament (MPFL) reconstruction with one of two graft constructs: 1) a graft constructed by the patient's own harvested hamstring tendon (HT), or 2) a graft constructed by the patient's own harvested quadriceps tendon (QT).

The HT graft is harvested from the hamstring tendons at the back of the thigh and above the knee, while the QT graft is harvested from the quadriceps tendon at the front of the thigh and above the knee. Each graft is harvested at the beginning of the surgical procedure, and then subsequently used to reconstruct the new MPFL. The intervention (the surgical procedure with one of the two graft types) will be administered by the treating orthopaedic surgeon.

While both constructs are generally used interchangeably, for the purpose of trial registration the 'intervention' is the QT graft.

The surgical time for both techniques remains the same, and takes approximately 45 minutes in length. This 45-minute period includes both the graft harvest and the reconstructive procedure (i.e. the entire surgical procedure). The appropriate intervention will be ensured in all patients via internal monitoring by the research team, liaising with a specific member of the research team that is independent to the research study team and on-site for all surgeries).

Following surgery, a standardized rehabilitation program will be followed by all patients, monitored by the patient's individual therapist. This rehabilitation program will generally require therapist visits every 1-2 weeks as required over the initial 12 weeks (as is the case through standard clinical practice), followed by periodic supervised therapy from 3-9 months post-surgery. Briefly and, standardized across all patients, early in-patient exercises will focus on regaining knee range of motion (ROM), patella mobility and pain/swelling reduction. From 2-3 weeks post-surgery, out-patient rehabilitation (including the exact exercises, together with recommended sets, repetitions and loads) will be dictated by individual patient physical conditioning and progression. An initial focus on exercises to restore movement and bilateral functional weight bearing strength will be prescribed. From 6-weeks post-surgery, a focus on single leg strength capacity will be undertaken, with a criterion-based return to jogging, as well as jumping and hopping exercises from 3 months post-surgery.
Intervention code [1] 333430 0
Treatment: Surgery
Description of the comparator or control
While both graft options are generally used interchangeably, for the purpose of trial registration the 'comparator' is the hamstring tendon (HT) graft construct.
Control group
Active

Outcomes
Primary outcome [1] 344682 0
Kujala Anterior Knee Pain Score – this score is an overall composite score that is calculated from subscale domains of pain, symptoms, function and perceived patellofemoral instability (this composite score is scored from 0–100).
Timepoint [1] 344682 0
12 months post-surgery
Secondary outcome [1] 458829 0
BANFF Patellofemoral Instability Instrument – this score is an overall composite score that is calculated from subscale domains of symptoms and physical complaints, school/work concerns, recreational and sporting participation, lifestyle concerns, and social and emotional concerns.
Timepoint [1] 458829 0
24 months post-surgery
Secondary outcome [2] 458830 0
Tegner Activity Score – this is a single score that grades the participant's current physical activity level, ranging from trivial daily activities and work-based activities through to recreational and sporting activities.
Timepoint [2] 458830 0
24 months post-surgery
Secondary outcome [3] 458831 0
Noyes Sports Activity Rating Scale – this is a single score that grades the participant's current level of competitive sports level and participation level.
Timepoint [3] 458831 0
24 months post-surgery
Secondary outcome [4] 458832 0
Active knee flexion range of motion (ROM) - this will be measured via the use of a long arm goniometer, measuring the angle made by three anatomical landmarks in a supine position (greater trochanter at the hip, lateral femoral condyle at the knee and the lateral malleouls at the ankle).
Timepoint [4] 458832 0
24 months post-surgery
Secondary outcome [5] 458833 0
Maximal isokinetic strength of the quadriceps muscles - this will be assessed using an isokinetic dynamometer (Isosport International, Gepps Cross, South Australia), measured through a range of 0-90° of knee flexion, at a single isokinetic angular velocity of 90°/s.
Timepoint [5] 458833 0
24 months post-surgery
Secondary outcome [6] 458834 0
Single hop for distance - this will be assessed using a tape measure.
Timepoint [6] 458834 0
24 months post-surgery
Secondary outcome [7] 458835 0
Triple hop for distance - this will be assessed using a tape measure.
Timepoint [7] 458835 0
24 months post-surgery
Secondary outcome [8] 458836 0
Triple crossover hop for distance - this will be assessed using a tape measure.
Timepoint [8] 458836 0
24 months post-surgery
Secondary outcome [9] 458837 0
Maximal isokinetic strength of the hamstrings muscles - this will be assessed using an isokinetic dynamometer (Isosport International, Gepps Cross, South Australia) through a range of 0-90° of knee flexion, at a single isokinetic angular velocity of 90°/s.
Timepoint [9] 458837 0
24 months post-surgery
Secondary outcome [10] 458838 0
Type of Surgical Complications - the type of complication (outside of the routine operative pathway) will be reported. These will be documented and obtained from the surgical operation notes, as well as via discussion with the treating orthopaedic surgeon.
Timepoint [10] 458838 0
Intra-operatively
Secondary outcome [11] 458839 0
Knee re-injuries - this will include a composite (and more holistic) review of each subsequent knee re-injury, that will include information on: (A) the nature (i.e. mechanism) of the re-injury as well as (B) the timing of each re-injury with reference to the primary surgery. Should these be reported at the time of a designated study monitoring visit, they will be discussed with the patient and the treating orthopaedic surgeon, and documented accordingly. Subsequently, medical records and any other investigations (such as medical imaging) if deemed appropriate can provide further information if required. Should these be experienced and reported outside (or between) designated study monitoring visits, then the treating surgeon will consult the patient as would be the case in routine clinical practice. Subsequently, medical records and any other investigations (such as medical imaging) if deemed appropriate can provide further information required.
Timepoint [11] 458839 0
24 months post-surgery
Secondary outcome [12] 458840 0
Radiology - Standing Maquet films: to monitor for any growth disturbance following surgery.
Timepoint [12] 458840 0
24 months post-surgery
Secondary outcome [13] 458841 0
Radiology - Dynamic Patellofemoral (PF) Computed Tomography (CT) imaging to quantify patellofemoral tracking.
Timepoint [13] 458841 0
12 months post-surgery
Secondary outcome [14] 458842 0
Adverse Events - information on the type, severity and timing of each adverse event will be reported. Should these be reported at the time of a designated study monitoring visit, they will be discussed with the patient and the treating orthopaedic surgeon, and documented accordingly based on professional clinical examination from the treating orthopaedic specialist. Subsequently, medical records and any other investigations (such as medical imaging) if deemed appropriate can provide further information if required. Should these be experienced and reported outside (or between) designated study monitoring visits, then the treating surgeon will consult the patient as would be the case in routine clinical practice. Again, the nature of the event, further investigations and/or treatment will be discussed with the patient and the treating orthopaedic surgeon, and further reported and documented accordingly. Subsequently, medical records and any other investigations (such as medical imaging) if deemed appropriate can provide further information required. Adverse events will be graded as follows: • Mild (Grade 1): Transient or mild discomfort; no limitation in activity; no intervention or therapy required (may include, though not limited to, events such as nausea). • Moderate (Grade 2): Mild to moderate limitation in activity; some assistance may be needed; no or minimal medical intervention/therapy required (may include, though not limited to, events such as infection at the incision site). • Severe (Grade 3): Marked limitation in activity; some assistance usually required; medical intervention/therapy required; hospitalization possible (may include, though not limited to, events such as transient nerve damage which may cause numbness, tingling, pain, and weakness). • Extreme (Grade 4): Extreme limitation in activity; significant assistance required; significant medical intervention/therapy required; hospitalization or hospice care probable; potentially life-threatening (may include, though not limited to, events such as blood clots, haemorrhaging and/or internal bleeding).
Timepoint [14] 458842 0
These are reviewed at every associated post-operative clinical time-point (including intra-operatively, as well as 2 weeks and 3, 6, 12 and 24 months post-surgery).
Secondary outcome [15] 460820 0
Active knee extension range of motion (ROM) - this will be measured via the use of a long arm goniometer, measuring the angle made by three anatomical landmarks in a supine position (greater trochanter at the hip, lateral femoral condyle at the knee and the lateral malleouls at the ankle).
Timepoint [15] 460820 0
24 months post-surgery
Secondary outcome [16] 460821 0
Number of Surgical Complications - the number of complications (outside of the routine operative pathway) will be reported.
Timepoint [16] 460821 0
24 months post-surgery
Secondary outcome [17] 460831 0
Radiology - Standing Maquet films: to evaluate lower limb alignment following surgery.
Timepoint [17] 460831 0
24 months post-surgery

Eligibility
Key inclusion criteria
· The individual is aged 8 to 18 years with patellofemoral instability.
· The individual clinically qualifies for MPFL reconstruction (with or without concomitant tibial tubercle transfer) based on clinical examination and radiological imaging.
· The individual has a history of recurrent patella instability episodes (dislocations or subluxations).
· The individual is undergoing unilateral MPFL reconstruction surgery.
· Individuals who have had contralateral MPFL reconstruction may be included if they meet all other inclusion and exclusion criteria.
· Individuals who have had previous guided growth surgery may be included if they meet all other inclusion and exclusion criteria; this will be recorded in baseline demographics.
Minimum age
8 Years
Maximum age
18 Years
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
· The individual (and parent/guardian where applicable) is unable or unwilling to provide written informed consent/assent as approved by the HREC.
· The individual (and parent/guardian) is unable or unwilling to complete the required pre-operative and post-operative follow up assessments (including imaging where applicable).
· Morbid obesity (at or beyond a boday mass index of 40).
· Significant comorbidities (e.g., Trisomy 21) that are likely to materially alter the post-operative recovery protocol or functional outcome assessment.
· Formal diagnosis of a connective tissue disorder (e.g., Ehlers-Danlos or Marfan’s syndrome).
· Clinically significant genu valgum deformity (intermalleolar distance at or beyond 10cm) at time of surgery (note: patients with previous guided growth surgery that has successfully corrected alignment may be eligible).
· Revision MPFL reconstruction or prior patellofemoral stabilisation surgery on the proposed surgical side.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Once eligibility has been confirmed and written informed consent has been obtained (participant and parent/legal guardian where applicable), participants will be randomly allocated in a 1:1 ratio to one of the two surgical study arms (QT vs HT graft), via a secure online randomisation platform (Sealed Envelope).
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Randomisation will be undertaken using a secure online randomisation platform (Sealed Envelope; 1 = QT, 2 = HT). The allocation sequence/ schedule will be generated and maintained by a member of the research team who is not involved in recruitment or outcome assessment.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Firstly, the means (SD, range) of all subjective and objective measures collected will be presented for the designated pre- and post-operative time-points. Furthermore, limb symmetry indices (LSIs) will be calculated for the physical performance measures by dividing the peak values on the operated limb by that recorded on the unaffected limb. The mean LSIs for each of the aforementioned hop tests will be presented and further categorized by the number and percentage of patients with LSIs below 90% and at or beyond 90% (as per clinical recommendations of unsatisfactory and satisfactory performance, respectively).

Repeated measures Analysis of Variance (ANOVA) will be employed to evaluate change over the pre- and post-operative timeline in all PROMs, as well as active knee ROM and physical performance measures (both absolute scores for the operated and non-operated limbs, as well as LSIs). ANOVA will also be employed to evaluate differences between the two groups (QT and HT MPFL reconstruction).

Where appropriate, statistical analysis will be performed using SPSS software (SPSS, Version 30.0, SPSS Inc., USA), while statistical significance was determined at alpha lower than 0.05.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
WA
Recruitment hospital [1] 29250 0
Perth Children's Hospital - Nedlands
Recruitment hospital [2] 29251 0
Hollywood Private Hospital - Nedlands
Recruitment hospital [3] 29252 0
St John of God Hospital, Murdoch - Murdoch
Recruitment hospital [4] 29253 0
Bethesda Hospital - Claremont
Recruitment postcode(s) [1] 45560 0
6009 - Nedlands
Recruitment postcode(s) [2] 45561 0
6150 - Murdoch
Recruitment postcode(s) [3] 45562 0
6010 - Claremont

Funding & Sponsors
Funding source category [1] 321338 0
Commercial sector/Industry
Name [1] 321338 0
Medacta Australia Pty Ltd
Country [1] 321338 0
Australia
Primary sponsor type
Hospital
Name
Perth Children's Hospital
Address
Country
Australia
Secondary sponsor category [1] 324074 0
None
Name [1] 324074 0
Address [1] 324074 0
Country [1] 324074 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319875 0
Child and Adolescent Health Service Human Research Ethics Committee
Ethics committee address [1] 319875 0
Ethics committee country [1] 319875 0
Australia
Date submitted for ethics approval [1] 319875 0
07/03/2026
Approval date [1] 319875 0
16/04/2026
Ethics approval number [1] 319875 0
RGS0000005493

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148682 0
Mr Dror Maor
Address 148682 0
Perth Children's Hopsital, 15 Hospital Avenue, Nedlands, Western Australia, 6009
Country 148682 0
Australia
Phone 148682 0
+61 8 6456 0347
Fax 148682 0
Email 148682 0
Contact person for public queries
Name 148683 0
Dror Maor
Address 148683 0
Perth Children's Hopsital, 15 Hospital Avenue, Nedlands, Western Australia, 6009
Country 148683 0
Australia
Phone 148683 0
+61 8 6456 0347
Fax 148683 0
Email 148683 0
Contact person for scientific queries
Name 148684 0
Dror Maor
Address 148684 0
Perth Children's Hopsital, 15 Hospital Avenue, Nedlands, Western Australia, 6009
Country 148684 0
Australia
Phone 148684 0
+61 8 6456 0347
Fax 148684 0
Email 148684 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Data is being collected and used only for the current study.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.